Who are Pyxis Oncology, Inc.'s main suppliers?

Pyxis Oncology, Inc. (PYXS) key suppliers include: Pfizer Inc., Pfizer Inc., PFIZER-INC, UNIVERSITY-OF-CHICAGO, ADC Therapeutics SA and 7 more. View the full supplier network at chainsifter.com/chain/PYXS.

Who are Pyxis Oncology, Inc.'s major customers?

Pyxis Oncology, Inc. (PYXS) key customers include: ADC Therapeutics SA, ADC Therapeutics SA, AstraZeneca PLC, AstraZeneca PLC, Celldex Therapeutics, Inc. and 3 more. View the full customer network at chainsifter.com/chain/PYXS.

What sector is Pyxis Oncology, Inc. in?

Pyxis Oncology, Inc. (PYXS) operates in the general sector. ChainSifter tracks its verified supply chain relationships including suppliers, customers, and strategic partners.

PYXS Supply Chain: Pyxis Oncology, Inc. Supplier List & 22 Relationships

12Suppliers

8Customers

2Debt Items

20Related Chains

Pyxis Oncology, Inc. Suppliers

Ticker	Name	Confidence	Evidence
PFE	Pfizer Inc.	92%	Reciprocal relationship from PFE graph: Reciprocal relationship from PYXS graph: Pfizer granted to the Company exclusive worldwide rights under Pfizer's Flexible Antibody Conjugation Technology
PFE	Pfizer Inc.	92%	Pfizer granted to the Company exclusive worldwide rights under Pfizer's Flexible Antibody Conjugation Technology
PFIZER-INC	PFIZER-INC	92%	The Company paid a combined $25.0 million for the license fee, consisting of an upfront cash payment of $5.0 million and issued 12,152,145 shares of Series B convertible preferred stock, which was co…
UNIVERSITY-OF-CHICAGO	UNIVERSITY-OF-CHICAGO	85%	the Company has the global right to develop and commercialize products that are covered by a valid claim of a licensed patent
ADCT	ADC Therapeutics SA	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
ADCT	ADC Therapeutics SA	72%	Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize o…
AZN	AstraZeneca PLC	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …
CLDX	Celldex Therapeutics, Inc.	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
GILD	Gilead Sciences, Inc.	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize …

Pyxis Oncology, Inc. Customers

Ticker	Name	Confidence	Evidence
ADCT	ADC Therapeutics SA	72%	Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from ADCT graph: Reciprocal relationship from PYXS graph: ter prove to have greater commercia…
ADCT	ADC Therapeutics SA	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
AZN	AstraZeneca PLC	72%	Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from AZN graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from AZN grap…
AZN	AstraZeneca PLC	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
CLDX	Celldex Therapeutics, Inc.	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
CLDX	Celldex Therapeutics, Inc.	72%	Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from CLDX g…
GILD	Gilead Sciences, Inc.	72%	ter prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Failure to prope…
GILD	Gilead Sciences, Inc.	72%	Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD graph: Reciprocal relationship from PYXS graph: Reciprocal relationship from GILD g…

Pyxis Oncology, Inc. Debt Obligations

Instrument	Description	Confidence	Evidence
PYXS-DEBT-11969	Xbrl Convertible	90%	xbrl convertible detail from xbrl 2021-12-31.
PYXS-DEBT	Debt stack $18.3M	90%	Market cache reports total debt of $18.3M.

Pyxis Oncology, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Pyxis Oncology, Inc..

Pyxis Oncology, Inc. Ownership

Holder	Name	Confidence	Evidence
PYXS-OWNER-PFIZER-INC	Pfizer Inc	90%	13F overlay lists Pfizer Inc as top holder; 77 tracked holders.

Pyxis Oncology, Inc. Extended Supply Chain Network

Ticker	Name	Chain Index	Hops	Relationship Types
CSTE	Caesarstone Ltd.	100.00	2
CHRS	Coherus Oncology, Inc.	100.00	2
BNR	Burning Rock Biotech Limited	100.00	2
AZN	AstraZeneca PLC	100.00	1	['customer', 'supplier']
CYTOF	Altamira Therapeutics Ltd.	100.00	2
BLLN	BillionToOne, Inc.	100.00	2
CTNM	Contineum Therapeutics, Inc.	100.00	2
ANIK	Anika Therapeutics, Inc.	100.00	2
BNRG	Brenmiller Energy Ltd	100.00	2
CCCC	C4 Therapeutics, Inc.	100.00	2
AORT	Artivion, Inc.	100.00	2
AVBP	ArriVent BioPharma, Inc.	100.00	2
CRBP	Corbus Pharmaceuticals Holdings, Inc.	100.00	2
CTMX	CytomX Therapeutics, Inc.	100.00	2
DEO	Diageo plc	100.00	2
BNBX	BNB Plus Corp.	100.00	2
AVIR	Atea Pharmaceuticals, Inc.	100.00	2
BIOA	BioAge Labs, Inc.	100.00	2
ANL	Adlai Nortye Ltd.	100.00	2
SNNUF	Smith & Nephew plc	100.00	2

Pyxis Oncology, Inc. Supply Chain